A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002

NCT ID: NCT06162299

Last Updated: 2025-02-24

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 16 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-07-01
• Study Completion Date: 2024-10-31

Brief Summary

This is the first-in-human Phase I, double-blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, immunogenicity and preliminary efficacy of the YSHBV-002 in the treatment of CHB in adults ≥18 years old. There will be 3 escalating doses of YS-HBV-002 to be administered intramuscularly: 0.5mL, 1.0mL, and 2.0mL.

Detailed Description

This is the first-in-human Phase I, double-blind, randomized, placebo-controlled, dose escalating study to evaluate the safety, immunogenicity and preliminary efficacy of the YSHBV-002 in the treatment of CHB in adults ≥18 years old. There will be 3 escalating doses of YS-HBV-002 to be administered intramuscularly: 0.5mL, 1.0mL, and 2.0mL. Enrollment in the study will sequentially start from the low dose 0.5mL as Group A, then to the mid-dose 1.0mL as Group B and lastly to the high dose of 2.0mL as Group C. Each group will have 16 patients enrolled. The first 4 enrollees in Group A will be sentinel patients and will be allocated at a 1:1 ratio to receive 0.5mL of either YS-HBV-002 or placebo (Table 3). As there is no comparable equivalent to YS-HBV-002 available in the market, the placebo of normal saline solution to be injected intramuscularly will serve as the control in this trial. The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 0.5mL of either YS-HBV-002 or placebo. The vaccination regimen will be 1 IM injection every 3 days in the deltoid muscle, alternately for approximately 6 weeks. A total of 14 injections will be administered to each patient.

Conditions

Chronic Hepatitis B

Study Design

• Allocation Method: NA
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Low dose 0.5mL

Group A ：The first 4 enrollees in Group A will be sentinel patients and will be allocated at a 1:1 ratio to receive 0.5mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 0.5mL of either YS-HBV-002 or placebo.

Group Type: EXPERIMENTAL

YS-HBV-002

Intervention Type: BIOLOGICAL

YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant

Mid-dose 1.0mL

Group B ：The first 4 enrollees in Group B will be sentinel patients and will be allocated at a 1:1 ratio to receive 1.0mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 1.0mL of either YS-HBV-002 or placebo.

Group Type: EXPERIMENTAL

YS-HBV-002

Intervention Type: BIOLOGICAL

YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant

High dose 2.0mL

Group C ：The first 4 enrollees in Group C will be sentinel patients and will be allocated at a 1:1 ratio to receive 2.0mL of either YS-HBV-002 or placebo(saline solution), The next 12 enrollees in Group A will be the main patients and will be allocated at 5:1 to receive 2.0mL of either YS-HBV-002 or placebo.

Group Type: EXPERIMENTAL

YS-HBV-002

Intervention Type: BIOLOGICAL

YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant

Interventions

YS-HBV-002

YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years during screening

2. Body Mass Index (BMI) of 18.5-30 kg/m2

3. Diagnosed or laboratory confirmed to have CHB

1. Have CHB infection for at least 6 months

2. HBsAg titer ≥ 1000 IU/mL

3. HBV DNA ≥ 2000 IU/mL

4. Serum alanine amino transferase (ALT) and aspartate aminotransferase (AST) ≤ 2 × upper limit of normal (ULN)

4. Able to provide informed consent

5. Able and willing to comply with all study procedures throughout the study period of approximately 3 months

6. For female subjects with childbearing potential: must agree to avoid pregnancy throughout the study period of approximately 3 months. Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must use an acceptable method of avoiding pregnancy during this period. Acceptable methods on avoiding pregnancy include: a sterile sexual partner, sexual abstinence (not engaging in sexual intercourse), hormonal contraceptives (oral, injection, transdermal patch, or implant), vaginal ring, intrauterine device (IUD), or the combination of a condom or diaphragm with a spermicide.

Exclusion Criteria

1. Pregnant or breastfeeding or intending to become pregnant within the projected duration of the trial

2. Transient elastography at screening revealing a FibroScan value of ≥ 9 kPa or a previous liver biopsy evidencing hepatic fibrosis at or within 24 months prior to vaccination

3. Patients with hepatitis caused by other etiologies

4. History of or manifestations of liver decompensation (e.g., Child-Pugh Class B or C, or ascites, gastrointestinal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis, etc....)

5. Currently participating in or has participated in a study with an IP within 30 days preceding Day 0

6. Fever (axillary temperature ≥ 37.8 ℃)

7. Subjects with abnormal indicators of blood biochemistry and other routine blood tests deemed clinically significant by the investigator

8. History of severe allergic reactions (such as acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema, or allergic abdominal pain) or allergy to any of the components of YS-HBV-002

9. Any history of anaphylaxis or angioedema after any vaccination

10. Allergy to kanamycin and aminoglycosides

11. Past or family history of convulsion, epilepsy, encephalopathy, or mental illness

12. Diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia, or other autoimmune diseases

13. History of coagulation dysfunction (e.g., coagulation factor deficiency, coagulation disease)

14. Bleeding disorder, or receipt of anticoagulants in the past 21 days preceding inclusion, contraindicating IM vaccination based on the investigator's judgement

15. Vaccinated with live attenuated vaccine within 1 month, or other vaccine/non-COVID-19 vaccine within 14 days prior to vaccination

16. Receiving immunotherapy or inhibitor therapy (consistently oral or infusion for more than 14 days) within 3 months prior to vaccination

17. Received systemic immunosuppressants within 4 months prior to vaccination or anticipating the need for immunosuppressant at any time during participation in the study. Topical or inhaled treatment is allowed if not used within 14 days prior to vaccination

18. Have received antiviral therapy for chronic hepatitis but have stopped for less than 30 days or plan to take antiviral therapy during the study

19. Received blood products within 3 months before vaccine administration

20. History of alcohol or drug abuse within the past 2 years

21. Any condition that, in the opinion of the investigator, would pose a health risk to the patient if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Yisheng Biopharma (Singapore) Pte. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ike Minerva, MD

Role: PRINCIPAL_INVESTIGATOR

Iloilo Doctors' Hospiyal

Locations

Iloilo Doctors' Hospital

Iloilo City, , Philippines

Countries

Philippines

Other Identifiers

YS-101

Identifier Type: -

Identifier Source: org_study_id